| Metric | Value ($ M) |
|---|---|
| Revenue | 197.56 |
| Total Income | 197.56 |
| Expenditure | 570.71 |
| PBT | -409.81 |
| Net Profit | -407.46 |
| OPM | — |
| NPM | — |
| EPS | -1.90 |
Revolution Medicines Reports Q3 2026 Financial Results and Corporate Progress
05 Nov 2026 · 6h ago
Summary
Revolution Medicines reported its third quarter 2026 financial results, highlighted by the U.S. FDA approval and launch of RASONQUE® (daraxonrasib), which generated $198 million in net product revenue for the partial quarter. The company also received a positive CHMP opinion for daraxonrasib in the European Union. Expenses increased significantly, with R&D at $417.1 million and SG&A at $153.3 million, contributing to a net loss of $407.5 million for the quarter. The company reiterated its full-year 2026 GAAP operating expense guidance and maintained a strong cash position of $3.7 billion.
Key Highlights
- 1
Revolution Medicines announced U.S. FDA approval and launch of RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer.
- 2
RASONQUE generated net product revenue of $198 million for the third quarter, reflecting a partial quarter of sales following its U.S. commercial launch.
- 3
The company received a positive CHMP opinion recommending marketing authorization of daraxonrasib in the European Union for metastatic pancreatic cancer.
- 4
Research and development expenses were $417.1 million for the quarter ended September 30, 2026, compared to $262.5 million for the same period in 2025.
- 5
Selling, general and administrative expenses increased to $153.3 million for the quarter ended September 30, 2026, from $52.8 million in the prior year period.
- 6
Net loss for the third quarter of 2026 was $407.5 million, compared to a net loss of $305.2 million for the third quarter of 2025.
- 7
Cash, cash equivalents and marketable securities stood at $3.7 billion as of September 30, 2026.
Management Comments
Mark A. Goldsmith
The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union. We are focused on delivering RASONQUE with urgency and supporting patients as they begin treatment while we rapidly scale our global commercialization capabilities in preparation for potential international approvals. We also continue to advance our broad, integrated portfolio of RAS(ON) inhibitors across common, difficult-to-treat RAS-addicted cancers.
Informational and educational content only. Not investment advice.